
Katherine E Burdick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9296578/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association between visceral adipose tissue and major depressive disorder across the lifespan: A scoping review. Bipolar Disorders, 2022, 24, 375-391.	1.9	8
2	Brain-derived neurotrophic factor and mood in perimenopausal depression. Journal of Affective Disorders, 2022, 300, 145-149.	4.1	2
3	Cognition in older adults with bipolar disorder: An ISBD task force systematic review and metaâ€analysis based on a comprehensive neuropsychological assessment. Bipolar Disorders, 2022, 24, 115-136.	1.9	24
4	The Effects of Peripheral Inflammation on the Brain—A Neuroimaging Perspective. Harvard Review of Psychiatry, 2022, 30, 54-58.	2.1	8
5	Brain Morphological Characteristics of Cognitive Subgroups of Schizophrenia-Spectrum Disorders and Bipolar Disorder: A Systematic Review with Narrative Synthesis. Neuropsychology Review, 2022, , 1.	4.9	4
6	Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disorders, 2022, 24, 354-374.	1.9	23
7	Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative. Bipolar Disorders, 2022, 24, 709-719.	1.9	16
8	Brain-Based Abnormalities in Bipolar Disorder: Neuroprogression (and Neurodevelopment). Biological Psychiatry, 2022, 91, 529-530.	1.3	0
9	Strategies and foundations for scientific discovery in longitudinal studies of bipolar disorder. Bipolar Disorders, 2022, 24, 499-508.	1.9	15
10	C-reactive protein and affective inhibition in bipolar disorder. Journal of Affective Disorders, 2022, 306, 39-46.	4.1	1
11	C-reactive protein is associated with cognitive performance in a large cohort of euthymic patients with bipolar disorder. Molecular Psychiatry, 2021, 26, 4096-4105.	7.9	26
12	Brain morphology does not clearly map to cognition in individuals on the bipolar-schizophrenia-spectrum: a cross-diagnostic study of cognitive subgroups. Journal of Affective Disorders, 2021, 281, 776-785.	4.1	11
13	Macro and micro sleep architecture and cognitive performance in older adults. Nature Human Behaviour, 2021, 5, 123-145.	12.0	75
14	The impact of COVID-19 on cognition in severe cases highlights the need for comprehensive neuropsychological evaluations in all survivors. Neuropsychopharmacology, 2021, 46, 2225-2225.	5.4	11
15	Recognising the relevance of cognitive dysfunction in the clinical management of bipolar disorder. Bipolar Disorders, 2021, 23, 414-415.	1.9	5
16	Defining Heterogeneous Cognitive Trajectories in Bipolar Disorder. Harvard Review of Psychiatry, 2021, Publish Ahead of Print, 298-302.	2.1	6
17	Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. Neuropsychopharmacology, 2021, 46, 1788-1801.	5.4	12
18	Pramipexole to Improve Cognition in Bipolar Disorder. Journal of Clinical Psychopharmacology, 2021, 41, 421-427	1.4	5

#	Article	IF	CITATIONS
19	The impact of lifetime interpersonal and intentional trauma on cognition and vulnerability to psychosis in bipolar disorder. BJPsych Open, 2021, 7, .	0.7	2
20	Cognitive heterogeneity is a key predictor of differential functional outcome in patients with bipolar disorder. European Neuropsychopharmacology, 2021, 53, 4-6.	0.7	18
21	Age moderates the relationship between affective response inhibition and bipolar disorder in adults. Journal of Affective Disorders, 2021, 295, 298-304.	4.1	0
22	Prevalence and factors associated with suicide ideation and psychiatric morbidity among inpatients of a general hospital: A consecutive threeâ€year study. Kaohsiung Journal of Medical Sciences, 2021, 37, 427-433.	1.9	3
23	Current understandings of the trajectory and emerging correlates of cognitive impairment in bipolar disorder: An overview of evidence. Bipolar Disorders, 2020, 22, 13-27.	1.9	89
24	Cognitive Control Network Homogeneity and Executive Functions in Late-Life Depression. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 213-221.	1.5	23
25	Patient interest in mental health mobile app interventions: Demographic and symptom-level differences. Journal of Affective Disorders, 2020, 263, 216-220.	4.1	16
26	The association between lithium use and neurocognitive performance in patients with bipolar disorder. Neuropsychopharmacology, 2020, 45, 1743-1749.	5.4	28
27	A molecular approach to treating cognition in schizophrenia by calcium channel blockade. Schizophrenia Research: Cognition, 2020, 21, 100180.	1.3	4
28	Emotion Processing, Cognition, and Social Functioning in Comorbid Psychosis Spectrum and Cocaine Use Disorders. Biological Psychiatry, 2020, 87, S169-S170.	1.3	0
29	Emotional processing subtypes in bipolar disorder: A cluster analysis. Journal of Affective Disorders, 2020, 266, 194-200.	4.1	9
30	The buildup of an urge in obsessive–compulsive disorder: Behavioral and neuroimaging correlates. Human Brain Mapping, 2020, 41, 1611-1625.	3.6	11
31	Cognitive validation of cross-diagnostic cognitive subgroups on the schizophrenia-bipolar spectrum. Journal of Affective Disorders, 2020, 266, 710-721.	4.1	27
32	TNF-α and its soluble receptors mediate the relationship between prior severe mood episodes and cognitive dysfunction in euthymic bipolar disorder. Brain, Behavior, and Immunity, 2020, 88, 403-410.	4.1	16
33	Entering the debate: Cognitive enhancement therapy for mood disorders: A new paradigm?. Bipolar Disorders, 2020, 22, 305-306.	1.9	3
34	Neurocognitive Subtypes in Bipolar Disorder: Clinical and Biological Correlates. Biological Psychiatry, 2020, 87, S10.	1.3	0
35	High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology, 2019, 44, 390-398.	5.4	19
36	Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways. American Journal of Human Genetics, 2019, 105, 334-350.	6.2	86

#	Article	IF	CITATIONS
37	Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force. Bipolar Disorders, 2019, 21, 686-719.	1.9	69
38	S121. REAL-WORLD FUNCTIONING IN SCHIZOPHRENIA: NEGATIVE SYMPTOMS AS A BRIDGE IN PATHWAYS FROM NEUROCOGNITION, SOCIAL COGNITION, AND FUNCTIONAL COMPETENCE. Schizophrenia Bulletin, 2019, 45, S352-S353.	4.3	0
39	The International Consortium Investigating Neurocognition in Bipolar Disorder (ICONIC ―BD). Bipolar Disorders, 2019, 21, 6-10.	1.9	12
40	4.4 THE INFLAMMATORY CASCADE AND COGNITIVE OUTCOME IN A TRANSDIAGNOSTIC COHORT. Schizophrenia Bulletin, 2019, 45, S92-S93.	4.3	1
41	S35. UNDERSTANDING THE RELATIONSHIP BETWEEN COGNITIVE HETEROGENEITY AND BRAIN MORPHOLOGY IN SCHIZOPHRENIA AND BIPOLAR DISORDER. Schizophrenia Bulletin, 2019, 45, S319-S319.	4.3	0
42	Functional neural mechanisms of sensory phenomena in obsessive-compulsive disorder. Journal of Psychiatric Research, 2019, 109, 68-75.	3.1	31
43	Contribution of Rare Copy Number Variants toÂBipolar Disorder Risk Is Limited to Schizoaffective Cases. Biological Psychiatry, 2019, 86, 110-119.	1.3	45
44	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. CNS Spectrums, 2019, 24, 154-162.	1.2	18
45	Premorbid adjustment trajectories in schizophrenia and bipolar disorder: A transdiagnostic cluster analysis. Psychiatry Research, 2019, 272, 655-662.	3.3	21
46	A preliminary investigation of impulsivity, aggression and white matter in patients with bipolar disorder and a suicide attempt history. Journal of Affective Disorders, 2019, 247, 88-96.	4.1	23
47	Conducting clinical studies targeting cognition in psychiatry: guiding principles and design. CNS Spectrums, 2019, 24, 16-21.	1.2	8
48	Effects of childhood trauma on adult moral decision-making: Clinical correlates and insights from bipolar disorder. Journal of Affective Disorders, 2019, 244, 180-186.	4.1	9
49	Adoption of Mobile Apps for Depression and Anxiety: Cross-Sectional Survey Study on Patient Interest and Barriers to Engagement. JMIR Mental Health, 2019, 6, e11334.	3.3	129
50	S21. Neural Mechanisms of Sensory Phenomena and Other Dimensional Symptoms in Obsessive-Compulsive Disorder. Biological Psychiatry, 2018, 83, S354-S355.	1.3	0
51	Social cognition moderates the relationship between neurocognition and community functioning in bipolar disorder. Journal of Affective Disorders, 2018, 235, 7-14.	4.1	36
52	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	2.3	18
53	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	12.8	484
54	F148. Emotion Processing Abnormalities in Bipolar Disorder: An fMRI Study Using an Emotional Go/Nogo Task. Biological Psychiatry, 2018, 83, S295.	1.3	0

#	Article	IF	CITATIONS
55	Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nature Genetics, 2018, 50, 912-919.	21.4	893
56	Organizational Learning Strategies and Verbal Memory Deficits in Bipolar Disorder. Journal of the International Neuropsychological Society, 2017, 23, 358-366.	1.8	9
57	New Genetic Discoveries in Anorexia Nervosa: Implications for the Field. American Journal of Psychiatry, 2017, 174, 821-822.	7.2	4
58	Neural correlates of interoception: Effects of interoceptive focus and relationship to dimensional measures of body awareness. Human Brain Mapping, 2017, 38, 6068-6082.	3.6	63
59	331. Premorbid Social and Academic Adjustment Trajectories in Schizophrenia and Bipolar Disorder: A Transdiagnostic Cluster Analysis. Biological Psychiatry, 2017, 81, S135-S136.	1.3	0
60	871. Modulation of the Insula and Somatosensory Cortex by Ondansetron. Biological Psychiatry, 2017, 81, S352.	1.3	0
61	Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets. Cell Reports, 2017, 21, 2597-2613.	6.4	103
62	Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and Be Most Promising for Predictive Algorithms for Conversion to Psychosis. Journal of Clinical Psychiatry, 2017, 78, e28-e40.	2.2	68
63	Neuropsychological Assessment and Psychological Tests. , 2016, , 24-27.		1
64	The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample. BMC Psychiatry, 2016, 16, 129.	2.6	61
65	The effects of cigarette smoking behavior and psychosis history on general and social cognition in bipolar disorder. Bipolar Disorders, 2016, 18, 528-538.	1.9	8
66	Coping strategies and real-world functioning in bipolar disorder. Journal of Affective Disorders, 2016, 198, 185-188.	4.1	28
67	Ageâ€associated alterations in corpus callosum white matter integrity in bipolar disorder assessed using probabilistic tractography. Bipolar Disorders, 2015, 17, 381-391.	1.9	20
68	Assessing Cognitive Function in Bipolar Disorder: Challenges and Recommendations for Clinical Trial Design. Journal of Clinical Psychiatry, 2015, 76, e342-e350.	2.2	63
69	Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. Neuropsychopharmacology, 2015, 40, 1084-1090.	5.4	117
70	The Neurobiology of Bipolar Disorder: Neuroimaging and Genetics Update. Focus (American) Tj ETQq0 0 0 rgBT /	Overlock 1 0.8	.0 Tf 50 142

71	Social cognition in patients with schizophrenia spectrum and bipolar disorders with and without psychotic features. Schizophrenia Research: Cognition, 2015, 2, 2-7.	1.3	14
72	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophrenia Bulletin, 2015, 41, 1237-1247.	4.3	45

#	Article	IF	CITATIONS
73	The association between childhood trauma and facial emotion recognition in adults with bipolar disorder. Psychiatry Research, 2015, 229, 771-776.	3.3	46
74	The relationship between sleep quality and neurocognition in bipolar disorder. Journal of Affective Disorders, 2015, 187, 156-162.	4.1	33
75	MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS. Depression and Anxiety, 2015, 32, 262-269.	4.1	55
76	Oxytocin and social cognition in affective and psychotic disorders. European Neuropsychopharmacology, 2015, 25, 265-282.	0.7	34
77	Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients. Neuropsychopharmacology, 2014, 39, 274-282.	5.4	33
78	Age-Related Differences in White Matter Tract Microstructure Are Associated with Cognitive Performance from Childhood to Adulthood. Biological Psychiatry, 2014, 75, 248-256.	1.3	122
79	Resting-State fMRI Connectivity Impairment in Schizophrenia and Bipolar Disorder. Schizophrenia Bulletin, 2014, 40, 100-110.	4.3	125
80	The Brief Assessment of Cognition In Affective Disorders (BAC-A):Performance of patients with bipolar depression and healthy controls. Journal of Affective Disorders, 2014, 166, 86-92.	4.1	43
81	Affective temperaments and neurocognitive functioning in bipolar disorder. Journal of Affective Disorders, 2014, 169, 51-56.	4.1	25
82	MATRICS cognitive consensus battery (MCCB) performance in children, adolescents, and young adults. Schizophrenia Research, 2014, 152, 223-228.	2.0	20
83	Overlapping and distinct gray and white matter abnormalities in schizophrenia and bipolar I disorder. Bipolar Disorders, 2013, 15, 680-693.	1.9	46
84	Impulsivity in bipolar disorder: relationships with neurocognitive dysfunction and substance use history. Bipolar Disorders, 2013, 15, 876-884.	1.9	39
85	Empirical Support for DSM-IV Schizoaffective Disorder: Clinical and Cognitive Validators from a Large Patient Sample. PLoS ONE, 2013, 8, e63734.	2.5	5
86	Abnormal Temporal Lobe White Matter as a Biomarker for Genetic Risk of Bipolar Disorder. Biological Psychiatry, 2013, 73, 177-182.	1.3	48
87	Independent Modulation of Engagement and Connectivity of the Facial Network During Affect Processing by <i>CACNA1C</i> and <i>ANK3</i> Risk Genes for Bipolar Disorder. JAMA Psychiatry, 2013, 70, 1303.	11.0	78
88	Assessing the potential to use neurocognition to predict who is at risk for developing bipolar disorder: A review of the literature. Cognitive Neuropsychiatry, 2013, 18, 129-145.	1.3	31
89	The Intersection of Symptomatology in Adult ADHD and Bipolar Disorder. Psychiatric Annals, 2013, 43, 20-25.	0.1	0
90	Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Research, 2012, 200, 242-245.	3.3	38

#	Article	IF	CITATIONS
91	Placebo-Controlled Adjunctive Trial of Pramipexole in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2012, 73, 103-112.	2.2	59
92	Emotional bias in unaffected siblings of patients with bipolar I disorder. Journal of Affective Disorders, 2012, 136, 1053-1058.	4.1	17
93	Relationship between suicidality and impulsivity in bipolar I disorder: a diffusion tensor imaging study. Bipolar Disorders, 2012, 14, 80-89.	1.9	108
94	Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophrenia Research, 2011, 126, 257-264.	2.0	162
95	Interaction between FEZ1 and DISC1 in Regulation of Neuronal Development and Risk for Schizophrenia. Neuron, 2011, 72, 559-571.	8.1	89
96	High Frequencies of De Novo CNVs in Bipolar Disorder and Schizophrenia. Neuron, 2011, 72, 951-963.	8.1	290
97	Emotional modulation of response inhibition in stable patients with bipolar I disorder: a comparison with healthy and schizophrenia subjects. Bipolar Disorders, 2011, 13, 164-172.	1.9	48
98	The MATRICS Consensus Cognitive Battery in Patients with Bipolar I Disorder. Neuropsychopharmacology, 2011, 36, 1587-1592.	5.4	163
99	Dopamine Transporter Gene Variant Affecting Expression in Human Brain is Associated with Bipolar Disorder. Neuropsychopharmacology, 2011, 36, 1644-1655.	5.4	129
100	Pharmacogenetic Approaches to Cognitive Enhancement in Schizophrenia. Harvard Review of Psychiatry, 2011, 19, 102-108.	2.1	11
101	Dr Gilbert and Colleagues Reply. Journal of Clinical Psychiatry, 2011, 72, 1698.	2.2	0
102	A role for white matter abnormalities in the pathophysiology of bipolar disorder. Neuroscience and Biobehavioral Reviews, 2010, 34, 533-554.	6.1	202
103	The International Society for Bipolar Disorders–Battery for Assessment of Neurocognition (ISBDâ€BANC). Bipolar Disorders, 2010, 12, 351-363.	1.9	218
104	Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disorders, 2010, 12, 364-375.	1.9	130
105	A Schizophrenia Risk Gene, ZNF804A, Influences Neuroanatomical and Neurocognitive Phenotypes. Neuropsychopharmacology, 2010, 35, 2284-2291.	5.4	87
106	Association of Genetic Variation in the <i><i>MET</i></i> Proto-Oncogene With Schizophrenia and General Cognitive Ability. American Journal of Psychiatry, 2010, 167, 436-443.	7.2	40
107	Meta-Analysis of Genetic Variation in DTNBP1 and General Cognitive Ability. Biological Psychiatry, 2010, 68, 1126-1133.	1.3	43
108	Cannabis use disorders in schizophrenia: Effects on cognition and symptoms. Schizophrenia Research, 2010. 120. 95-100.	2.0	62

#	Article	IF	CITATIONS
109	The role of general intelligence as an intermediate phenotype for neuropsychiatric disorders. Cognitive Neuropsychiatry, 2009, 14, 299-311.	1.3	31
110	Molecular differentiation of schizoaffective disorder from schizophrenia using <i>BDNF</i> haplotypes. British Journal of Psychiatry, 2009, 194, 313-318.	2.8	36
111	A Voxel-Based Diffusion Tensor Imaging Study of White Matter in Bipolar Disorder. Neuropsychopharmacology, 2009, 34, 1590-1600.	5.4	95
112	Volumetric and shape analysis of the thalamus in firstâ€episode schizophrenia. Human Brain Mapping, 2009, 30, 1236-1245.	3.6	53
113	DTNBP1 is associated with imaging phenotypes in schizophrenia. Human Brain Mapping, 2009, 30, 3783-3794.	3.6	32
114	Attention and psychomotor functioning in bipolar depression. Psychiatry Research, 2009, 166, 192-200.	3.3	31
115	Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophrenia Research, 2009, 107, 262-266.	2.0	52
116	Genetic variation in the DAOA gene complex: Impact on susceptibility for schizophrenia and on cognitive performance. Schizophrenia Research, 2008, 103, 169-177.	2.0	28
117	DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biological Psychology, 2008, 79, 103-110.	2.2	88
118	Gray matter structural alterations in obsessive–compulsive disorder: Relationship to neuropsychological functions. Psychiatry Research - Neuroimaging, 2008, 164, 123-131.	1.8	53
119	The Genetics of Symptom-Based Phenotypes: Toward a Molecular Classification of Schizophrenia. Schizophrenia Bulletin, 2008, 34, 1047-1053.	4.3	80
120	Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: Evidence of epistasis and competitive binding. Human Molecular Genetics, 2008, 17, 2462-2473.	2.9	101
121	Neurocognitive profile analysis in obsessive-compulsive disorder. Journal of the International Neuropsychological Society, 2008, 14, 640-645.	1.8	34
122	Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19942-19947.	7.1	367
123	Cognitive Dysfunction in Bipolar Disorder. CNS Drugs, 2007, 21, 971-981.	5.9	55
124	DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophrenia Research, 2007, 89, 169-172.	2.0	102
125	Iowa Gambling Task in schizophrenia: A review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophrenia Research, 2007, 92, 74-84.	2.0	166
126	Disrupted in Schizophrenia 1 Genotype and Positive Symptoms in Schizophrenia. Biological Psychiatry, 2007, 61, 1208-1210.	1.3	73

#	Article	IF	CITATIONS
127	COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disorders, 2007, 9, 370-376.	1.9	80
128	Early-onset schizophrenia is associated with impaired adolescent development of attentional capacity using the identical pairs continuous performance test. Schizophrenia Research, 2006, 81, 157-166.	2.0	25
129	Decision-making impairments in adolescents with early-onset schizophrenia. Schizophrenia Research, 2006, 85, 113-123.	2.0	83
130	Deficits in memory strategy use are related to verbal memory impairments in adolescents with schizophrenia-spectrum disorders. Schizophrenia Research, 2006, 85, 201-212.	2.0	39
131	Ziprasidone-induced cognitive enhancement in schizophrenia: Specificity or pseudospecificity?. Schizophrenia Research, 2006, 87, 181-184.	2.0	17
132	COMT genotype and manic symptoms in schizophrenia. Schizophrenia Research, 2006, 87, 28-31.	2.0	22
133	Neurocognition as a Stable Endophenotype in Bipolar Disorder and Schizophrenia. Journal of Nervous and Mental Disease, 2006, 194, 255-260.	1.0	100
134	Emotion-based decision-making in healthy subjects: short-term effects of reducing dopamine levels. Psychopharmacology, 2006, 188, 228-235.	3.1	93
135	Dysbindin Genotype and Negative Symptoms in Schizophrenia. American Journal of Psychiatry, 2006, 163, 532-534.	7.2	101
136	Genetic variation in DTNBP1 influences general cognitive ability. Human Molecular Genetics, 2006, 15, 1563-1568.	2.9	160
137	DISC1 and neurocognitive function in schizophrenia. NeuroReport, 2005, 16, 1399-1402.	1.2	105
138	Assessing cognitive deficits in bipolar disorder: Are self-reports valid?. Psychiatry Research, 2005, 136, 43-50.	3.3	128
139	Neurocognitive Profile in Adolescents with Early-Onset Schizophrenia: Clinical Correlates. Biological Psychiatry, 2005, 58, 705-712.	1.3	111
140	Preliminary Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Added to Mood Stabilizers for Treatment-Resistant Bipolar Depression. American Journal of Psychiatry, 2004, 161, 564-566.	7.2	305
141	Levetiracetam for Acute Mania. American Journal of Psychiatry, 2002, 159, 148-148.	7.2	110
142	Executive Functions and P300 Latency in Elderly Depressed Patients and Control Subjects. American Journal of Geriatric Psychiatry, 2000, 8, 57-65.	1.2	46